5 recruiting, 4 unknown, 2 completed, 2 not yet recruiting. 10 Phase 2, 7 Phase 1, 1 Not applicable, 1 Phase 3.
Follow Beijing Tide Pharmaceutical Co., Ltd: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb) TRD205 Tablets, oral; 400 mg initial dose, then 200 mg q12h for 3 doses; total 4 doses, TRD205 Tablets, oral; 800 mg initial dose, then 400 mg q12h; total 4 doses, TRD205 Tablets, oral; 1200 mg initial dose, then 600 mg q12h; total 4 doses - Postoperative Analgesia After Unilateral Hip Arthroplasty | Phase 2 | Recruiting | Beijing Tide Pharmaceutical Co., Ltd | 200 | 2026-03-18 | 2026-04-22 |
| A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF) TDI01 - Idiopathic Pulmonary Fibrosis (IPF) | Phase 3 | Recruiting | Beijing Tide Pharmaceutical Co., Ltd | 508 | 2025-12-24 | 2026-03-11 |
| An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg - Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 / Phase 2 | Recruiting | Beijing Tide Pharmaceutical Co., Ltd | 266 | 2025-12-03 | 2026-01-28 |
| Phase I Study of CPD704 Inhalation Suspension in Healthy Subjects CPD704 Inhalation Suspension, CPD704 placebo - Healthy, Healthy Participants | Phase 1 | Recruiting | Beijing Tide Pharmaceutical Co., Ltd | 90 | 2025-10-21 | 2025-12-24 |
| To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hip Arthroplasty TRD205 tablets, placebo - Postoperative Analgesia After Unilateral Hip Arthroplasty | Phase 2 | Not yet recruiting | Beijing Tide Pharmaceutical Co., Ltd | 40 | 2025-09-26 | 2025-08-13 |
| To Evaluate the Safety, Efficacy and Kinetic Characteristics of TRD205 Tablets for Postoperative Analgesia After Unilateral Hallux Valgus Orthopedic Surgery TRD205 tablets, Placebo - Postoperative Analgesia After Unilateral Hallux Valgus Correction Surgery | Phase 1 | Not yet recruiting | Beijing Tide Pharmaceutical Co., Ltd | 32 | 2025-08-26 | 2025-08-13 |
| To Evaluate the Efficacy and Safety of TRD205 Tablets in the Treatment of Chronic Postoperative Neuralgia TRD205 tablets, Placebo - Chronic Postoperative Neuralgia | Phase 2 | Enrolling by invitation | Beijing Tide Pharmaceutical Co., Ltd | 184 | 2025-04-09 | 2025-08-17 |
| TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD)) TDI01 suspension - GVHD, Chronic | Phase 1 / Phase 2 | Active not recruiting | Beijing Tide Pharmaceutical Co., Ltd | 60 | 2024-02-06 | 2025-09-26 |
| A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough TCR1672 tablet - Refractory Chronic Cough | Phase 1 / Phase 2 | Unknown | Beijing Tide Pharmaceutical Co., Ltd | 72 | 2024-02-01 | 2024-01-19 |
| Single and Multiple Ascending Doses and Food Effect Study of TRD205 in Healthy Volunteers TRD205, Placebo - Healthy | Phase 1 | Completed | Beijing Tide Pharmaceutical Co., Ltd | 151 | 2024-01-26 | 2025-08-14 |
| A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis TDI01 suspension - Idiopathic Pulmonary Fibrosis | Phase 2 | Unknown | Beijing Tide Pharmaceutical Co., Ltd | 120 | 2023-11-02 | 2023-11-02 |
| A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. TCC1727 tablet（1）, TCC1727 tablet（2） - Patients with Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Beijing Tide Pharmaceutical Co., Ltd | 56 | 2023-08-07 | 2025-03-21 |
| Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal Surgery Meloxicam Injection 30mg, Meloxicam Injection 60mg, Nacl 0.9% - Pain, Post-operative | Phase 2 | Unknown | Beijing Tide Pharmaceutical Co., Ltd | 108 | 2023-07-01 | 2023-07-18 |
| Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury PC-SOD, placebo - Myocardial Reperfusion Injury | Phase 2 | Unknown | Beijing Tide Pharmaceutical Co., Ltd | 120 | 2019-06-18 | 2019-09-26 |
| Pronase Improves Efficacy of Chromoendoscopy Screening on Esophageal Cancer Pronase, Control - Esophageal Neoplasms | Not applicable | Completed | Xijing Hospital of Digestive Diseases | 1000 | 2014-01-01 | 2016-03-29 |
Idiopathic Pulmonary Fibrosis (2) · Ataxia Telangiectasia (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Non-Small-Cell Lung (1) · Chronic Cough (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Melanoma (1) · Myocardial Reperfusion Injury (1) · Pain, Postoperative (1) · Stomach Neoplasms (1)
Capsules (1) · Celecoxib (1) · Meloxicam (1) · Pronase (1) · Sodium Chloride (1)
China (13)